{"disease":{"id":"hepatitis-c-recurrent","name":"hepatitis c recurrent"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03145844","title":"Direct Acting Agents in Hepatitis C Patients","phase":"","overall_status":"COMPLETED","enrollment_count":2700,"lead_sponsor_name":"Fehmi Tabak","has_results":false},{"nct_id":"NCT04004299","title":"Self-testing for HCV Re-infection in MSM","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT02143401","title":"Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}